Last updated: 14 March 2023 at 4:48pm EST

Andrew Balo Net Worth

The estimated Net Worth of Andrew K Balo is at least 41.3 百万$ dollars as of 9 September 2021. Mr. Balo owns over 5,597 units of Dexcom Inc stock worth over 517,154$ and over the last 19 years he sold DXCM stock worth over 37,753,374$. In addition, he makes 3,022,690$ as Executive Vice President - Regulatory Strategy、 Clinical Affairs、 and Strategic Partnership Development at Dexcom Inc.

Mr. Balo DXCM stock SEC Form 4 insiders trading

Andrew has made over 101 trades of the Dexcom Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 5,597 units of DXCM stock worth 3,060,328$ on 9 September 2021.

The largest trade he's ever made was exercising 55,000 units of Dexcom Inc stock on 20 June 2016 worth over 175,450$. On average, Andrew trades about 6,682 units every 26 days since 2005. As of 9 September 2021 he still owns at least 7,553 units of Dexcom Inc stock.

You can see the complete history of Mr. Balo stock trades at the bottom of the page.

Andrew Balo biography

Andrew K. Balo serves as Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development of the Company. He has served as our Executive Vice President of Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development since May 2016. From January 2015 until April 2016 Mr. Balo served as our Executive Vice President, Clinical, Regulatory and Quality. From March 2008 to January 2015, Mr. Balo served as our Senior Vice President of Clinical and Regulatory Affairs, and from February 2002 to March 2008, served as our Vice President of Clinical and Regulatory Affairs. From June 1999 to February 2002, Mr. Balo served as Vice President, Regulatory and Clinical Affairs of Innercool Therapies, Inc., a medical technology company. Mr. Balo has held several positions at St. Jude Medical including Clinical, Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company. Mr. Balo received a B.S. from the University of Maryland.

What is the salary of Andrew Balo?

As the Executive Vice President - Regulatory Strategy、 Clinical Affairs、 and Strategic Partnership Development of Dexcom Inc, the total compensation of Andrew Balo at Dexcom Inc is 3,022,690$. There are 3 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of 10,279,400$.

How old is Andrew Balo?

Andrew Balo is 72, he's been the Executive Vice President - Regulatory Strategy、 Clinical Affairs、 and Strategic Partnership Development of Dexcom Inc since 2016. There are 2 older and 27 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..

What's Andrew Balo's mailing address?

Andrew's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.

Insiders trading at Dexcom Inc

Over the last 20 years, insiders at Dexcom Inc have traded over 724,717,982$ worth of Dexcom Inc stock and bought 165,450 units worth 3,489,100$ . The most active insiders traders include Sean Carney、Kim D Blickenstaff、Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of 892,438$. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth 29,458$.

What does Dexcom Inc do?

founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.

Complete history of Mr. Balo stock trades at Dexcom Inc

インサイダー	取引取引	合計金額
Andrew K Balo EVP Regulatory Strategy Clinic	販売	3,060,328$ 9 Sep 2021
Andrew K Balo EVP Regulatory Strategy Clinic	販売	1,422,254$ 3 Aug 2021
Andrew K Balo EVP Regulatory Strategy Clinic	販売	1,279,236$ 6 Jul 2021
Andrew K Balo EVP Regulatory Strategy Clinic	販売	896,625$ 3 Jun 2021
Andrew K Balo EVP Regulatory Strategy Clinic	販売	2,020,013$ 10 Mar 2021
Andrew K Balo EVP Regulatory Strategy Clinic	販売	2,088,472$ 15 Sep 2020
Andrew K Balo EVP Regulatory Strategy Clinic	販売	1,824,214$ 9 Sep 2020
Andrew K Balo EVP Regulatory Strategy Clinic	販売	2,390,117$ 15 Jun 2020
Andrew K Balo EVP Regulatory Strategy Clinic	販売	1,895,879$ 15 Apr 2020
Andrew K Balo EVP Regulatory Strategy Clinic	販売	2,161,196$ 11 Mar 2020
Andrew K Balo EVP Regulatory Strategy Clinic	販売	361,384$ 18 Sep 2019
Andrew K Balo EVP Regulatory Strategy Clinic	販売	1,380,257$ 9 Sep 2019
Andrew K Balo EVP Regulatory Strategy Clinic	販売	6,290$ 3 Sep 2019
Andrew K Balo EVP Regulatory Strategy Clinic	販売	978,125$ 5 Jun 2019
Andrew K Balo EVP Regulatory Strategy Clinic	販売	1,558,838$ 12 Mar 2019
Andrew K Balo EVP Regulatory Strategy Clinic	販売	606,150$ 14 Dec 2018
Andrew K Balo EVP Regulatory Strategy Clinic	販売	715,650$ 14 Nov 2018
Andrew K Balo EVP Regulatory Strategy Clinic	販売	623,950$ 12 Oct 2018
Andrew K Balo EVP Regulatory Strategy Clinic	販売	725,850$ 14 Sep 2018
Andrew K Balo EVP Regulatory Strategy Clinic	販売	803,187$ 10 Sep 2018
Andrew K Balo EVP Regulatory Strategy Clinic	販売	621,250$ 14 Aug 2018
Andrew K Balo EVP Regulatory Strategy Clinic	販売	497,800$ 16 Jul 2018
Andrew K Balo EVP Regulatory Strategy Clinic	販売	198,691$ 11 Dec 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	389,400$ 29 Nov 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	234,444$ 11 Sep 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	230,908$ 10 Aug 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	228,960$ 10 Jul 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	220,992$ 12 Jun 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	230,176$ 10 May 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	250,208$ 10 Apr 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	248,672$ 10 Mar 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	253,760$ 10 Feb 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	253,760$ 10 Feb 2017
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	31,360$ 10 Jan 2017
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	31,360$ 10 Jan 2017
Andrew K Balo EVP Regulatory Strategy Clinic	販売	411,303$ 19 Oct 2016
Andrew K Balo EVP Regulatory Strategy Clinic	販売	412,750$ 5 Oct 2016
Andrew K Balo EVP Regulatory Strategy Clinic	販売	464,350$ 21 Sep 2016
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	15,947$ 7 Sep 2016
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	15,950$ 24 Aug 2016
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	15,950$ 10 Aug 2016
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	15,950$ 27 Jul 2016
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	15,950$ 13 Jul 2016
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	15,950$ 29 Jun 2016
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	175,450$ 20 Jun 2016
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	23,925$ 17 Dec 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	23,925$ 3 Dec 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	23,925$ 25 Nov 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	31,900$ 23 Nov 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	23,925$ 11 Nov 2015
Andrew K Balo EVP Regulatory Strategy Clinic	販売	369,665$ 20 Oct 2015
Andrew K Balo EVP Regulatory Strategy Clinic	販売	676,095$ 6 Oct 2015
Andrew K Balo EVP Regulatory Strategy Clinic	販売	791,558$ 21 Sep 2015
Andrew K Balo EVP Regulatory Strategy Clinic	販売	671,475$ 8 Sep 2015
Andrew K Balo EVP Regulatory Strategy Clinic	販売	693,525$ 20 Aug 2015
Andrew K Balo EVP Regulatory Strategy Clinic	販売	712,800$ 6 Aug 2015
Andrew K Balo EVP Regulatory Strategy Clinic	販売	865,943$ 22 Jul 2015
Andrew K Balo EVP Regulatory Strategy Clinic	販売	360,509$ 8 Jul 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	54,615$ 23 Jun 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	73,500$ 9 Jun 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	73,500$ 18 May 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	73,500$ 4 May 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	73,500$ 23 Apr 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	73,500$ 9 Apr 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	73,500$ 25 Mar 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	73,500$ 11 Mar 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	73,500$ 24 Feb 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	73,500$ 10 Feb 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	125,258$ 26 Jan 2015
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	76,300$ 26 Dec 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	76,300$ 11 Dec 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	76,300$ 25 Nov 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	76,300$ 11 Nov 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	76,300$ 27 Oct 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	76,300$ 13 Oct 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	76,300$ 25 Sep 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	76,300$ 10 Sep 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	76,300$ 25 Aug 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	63,800$ 22 Aug 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	89,400$ 11 Aug 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	89,400$ 25 Jul 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	89,400$ 11 Jul 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	89,400$ 25 Jun 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	89,400$ 11 Jun 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	72,500$ 27 May 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	72,500$ 12 May 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	72,500$ 25 Apr 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	72,500$ 11 Apr 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	72,500$ 25 Mar 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	72,500$ 11 Mar 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	72,500$ 25 Feb 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	107,800$ 11 Feb 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	143,000$ 27 Jan 2014
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	143,000$ 13 Jan 2014
Andrew K Balo EVP Regulatory Strategy Clinic	販売	488,108$ 3 Dec 2013
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	101,333$ 11 Nov 2013
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	24,000$ 13 Jun 2013
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	108,000$ 13 May 2013
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	7,708$ 11 Mar 2013
Andrew K Balo EVP Regulatory Strategy Clinic	販売	178,257$ 13 Dec 2012
Andrew K Balo EVP Regulatory Strategy Clinic	オプション行使	14,233$ 18 May 2012

Dexcom Inc executives and stock owners

Dexcom Inc executives and other stock owners filed with the SEC include:

Kevin Sayer,
Chairman of the Board, President, Chief Executive Officer
Quentin Blackford,
Chief Financial Officer, Chief Operating Officer
Richard Doubleday,
Executive Vice President, Chief Commercial Officer
Andrew Balo,
Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development
Steven Pacelli,
Executive Vice President - Strategy and Corporate Development
Donald Abbey,
Executive Vice President - Quality and Regulatory Affairs
Kevin Ronald Sayer,
Exec. Chairman, CEO & Pres
Jacob Steven Leach,
Exec. VP & CTO
Bridgette Heller,
Independent Director
Mark Foletta,
Lead Independent Director
Eric Topol,
Independent Director
Jay Skyler,
Independent Director
Nicholas Augustinos,
Independent Director
Steven Altman,
Independent Director
Barbara Kahn,
Independent Director
Richard Collins,
Independent Director
Kyle Malady,
Independent Director
Karen Dahut,
Independent Director
Shelly Selvaraj,
Senior Vice President - Information Technology
Jeffrey Moy,
Senior Vice President - Operations
Jereme Sylvain,
Senior Vice President - Finance, Chief Accounting Officer
Patrick Murphy,
Executive Vice President, Chief Legal Officer
Jake Leach,
Executive Vice President, Chief Technology Officer
Shelly Ramasamy Selvaraj,
Sr. VP of Information Technology
Donald M. Abbey,
Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs
Steven R. Pacelli,
Exec. VP & MD of Dexcom Ventures
Andrew K. Balo,
Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel.
Sadie M. Stern,
Exec. VP & Chief HR Officer
Chad M. Patterson,
Exec. VP of Global Marketing
Sean Christensen,
Director of Corp. Affairs & Head of Investor Relations
Jereme M. Sylvain,
Exec. VP, CFO & Chief Accounting Officer
John Lister,
VP, Legal Affairs
Terrance H Gregg,
Director
Jess Roper,
VP, CFO
Jorge A Valdes,
Vice President of Engineering
Girish Naganathan,
EVP Chief Technology Officer
Heather S Ace,
SVP Human Resources
Kevin M Sun,
VP, Corp Controller & Treasury
Jonathan T Md Lord,
Director
Glen D Nelson,
Director
Peter Gerhardsson,
VP, Int'l Business Development
David Carner,
VP, Quality Assurance
Laura Johnson,
V.P., Intellectual Property
Martin Doordan,
Director
Sean Carney,
Director
John Riolo,
VP of Quality Assurance
Claudia Graham,
VP, Marketing
Donald A Lucas,
Director
Donald L Lucas,
Director
Mark Brister,
VP, Advanced Development Teams
Richard Yang,
V.P., Strategic Affairs
James H Brauker,
VP, Research & Development
Rodney L Kellogg,
Vice President of Sales
Andrew P Rasdal,
President and CEO
Steven J Kemper,
Chief Financial Officer
Kim D Blickenstaff,
Director
Tae Andrews,
Vice President of Marketing
Paul Travelers Companies In...,
Pincus Private Equity Viii ...,
Brenton Karl Ahrens,
Director
Nancy Sfog City Management ...,
Equity Partners Ii Llccanaa...,
Paul Travelers Companies In...,
Eric A Charmers Landing Llc...,
Scott Lwindamere Llcwindame...,
Equity Partners Ii Llc Waub...,
Teri L Lawver,
EVP Chief Commercial Officer
Paul R Flynn,
EVP Global Revenue
Matthew Vincent Dolan,
EVP Strategy and Corporate Dev
Sumi Shrishrimal,
SVP Chief Risk Officer
Chad Patterson,
EVP Global Marketing
Barry J. Regan,
EVP Operations
Jacob Steven Leach,
EVP, Chief Operating Officer
Rimma Driscoll,
Director
Michael Jon Brown,
EVP, Chief Legal Officer
Sadie Stern,
EVP, Chief HR Officer